Race to Lead FDA Intensifies as Makary Departs; Sen. Cassidy Faces Political Crossfire

The sudden departure of Dr. Marty Makary from the Food and Drug Administration has triggered a high-stakes search for his successor, with Sen. Bill Cassidy (R-La.) emerging as a polarizing contender caught between his medical expertise and Senate responsibilities.

“Cassidy’s dual identity as a physician and a senator makes him uniquely qualified yet politically vulnerable,” said Dr. Joshua Sharfstein, former FDA deputy commissioner. “The agency needs steady hands, not a partisan battlefield.”

Background

Makary, known for his unorthodox style and recent revelation of a guilty pleasure for organic yogurt-covered goji berries in Men’s Health, is leaving the FDA at a critical juncture. His tenure oversaw accelerated drug approvals and pandemic-era regulatory shifts, but internal tensions over transparency and conflicts of interest persisted.

The vacancy comes as the FDA grapples with reauthorizing user fees, integrating artificial intelligence into medical devices, and addressing public skepticism about vaccine safety. Sources inside the agency describe a morale crisis, with many staffers anxious about political interference.

Dr. Cassidy vs. Sen. Cassidy

Bill Cassidy, a gastroenterologist and three-term senator, now faces an agonizing choice: pursue the FDA commissioner role or remain in the Senate, where Republicans hold a fragile majority. “Everyone in Louisiana politics feels sorry for Bill Cassidy,” said a senior state party official who spoke on condition of anonymity. “He’s torn between serving patients and serving his party.”

Cassidy’s voting record—including support for drug pricing reform and vaccine mandates—has drawn fire from both conservatives and progressives. His potential nomination would require a grueling confirmation battle, likely reopening debates over pharmaceutical regulation and COVID-19 policies.

What This Means

The next FDA leader will inherit a portfolio in flux: oversight of novel gene therapies, a backlog of generic drug applications, and simmering disputes over accelerated approval pathways. “We cannot afford a prolonged leadership vacuum,” warned Diana Zuckerman, president of the National Center for Health Research. “Every month without a permanent commissioner delays critical decisions on safety and innovation.”

If Cassidy accepts the nomination, his Senate departure would shift the balance of power in Washington. If he declines, the administration must pivot to other candidates—potentially including former FDA officials or academic researchers—each carrying their own political baggage.

Makary’s exit, meanwhile, has already sparked internal reorganization. Deputy Commissioner Dr. Janet Woodcock is expected to serve as acting chief until a successor is confirmed, but her interim role may limit major policy moves.

“The hunt for FDA’s next leader is not just about one person,” Sharfstein added. “It’s a referendum on the agency’s independence in an era of hyperpartisanship.”

Follow our ongoing coverage of FDA leadership here and analysis of policy implications.